Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
This was a busy week in the GLP-1 arena. An FDA advisory panel last week overwhelmingly recommended approval of Novo Nordisk’s latest weight-loss drug, Saxenda. This medication, which is liraglutide 3 mg, was recommended as an adjunct to diet and exercise in adults with a BMI of 30 or more, or 27 or more with at least one weight-related comorbidity.
Eli Lilly also got approval for their once-weekly dulaglutide based on six clinical trials involving a total of 3,342 patients who received the drug. It was studied as a stand-alone therapy and in combination with metformin, sulfonylurea, thiazolidinedione, and prandial insulin.
For those of you who want to know more be sure to check out our September GLP-1 Special Edition coming out next week.
The idea of using a GLP-1 analogs for weight loss is not new and if you check out Item #6, losing weight makes extra sense when you see how much money we save on diabetes patients who have healthy lifestyle habits.
We all know that whenever we talk weight loss, the words ‘diet’ and ‘exercise’ always come into play. This week, our exercise guru Dr. Sheri Colberg shares the first of three columns on why daily movement improves brain health as well as blood sugars. In Part 1, she discusses Gene Activation and More.
*****
Dave Joffe, Editor-in-chief